Author: Ramona Adams|| Date Published: December 7, 2016
SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations.
SRI said Tuesday its biosciences division will manufacture and characterize drug products to support the development of microbicide and non-vaccine pre-exposure agents through preclinical and clinical studies for the NIH’s National Institute of Allergy and Infectious Diseases and the Division of AIDS.
The company will also support activities that the Food and Drug Administration requires to move products into clinical tests.
Gita Shankar, an SRI director, has led a project to develop a multipurpose HIV prevention microbicide bioadhesive gel under an NIAID grant the company received in 2010.
SRI also produced drug products and supplied clinical sites with microbicides and contraceptive controls between 2000 and 2004.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations.
